Quick Answer: What Is the Wolverine Stack?

The Wolverine Stack is the popular name for combining BPC-157 and TB-500, two experimental peptides studied primarily for different aspects of tissue repair. BPC-157 has preclinical evidence involving blood-vessel signaling, tendon-cell migration and tissue protection, while thymosin-beta-4—the parent molecule related to TB-500—has research involving cell migration and wound repair. The combination is popular in peptide circles, but it has not been proven in controlled human clinical trials.

Summary

In this conversation, Funk Roberts discusses the Wolverine stack, a combination of two peptides, BPC 157 and TB500, aimed at enhancing recovery and tissue repair for men over 40. He explains the individual roles of each peptide, their mechanisms, and shares personal experiences with their use. The conversation emphasizes the importance of a healthy lifestyle alongside peptide use for optimal results.

Takeaways

• The Wolverine stack is for men over 40, 50, 60, and beyond.
• BPC 157 helps create a better repair environment.
• TB500 aids in the movement of repair cells to injury sites.
• Both peptides work synergistically to enhance recovery.
• Anecdotal evidence supports the effectiveness of the stack.
• Personal experience shows positive results in recovery.
• Healthy lifestyle is crucial for peptide effectiveness.
• Peptides are not a substitute for proper nutrition and training.
• Research on peptides is still developing, especially in humans.
• The Wolverine stack is a promising option for recovery.

Medical Disclaimer

This article is for informational and educational purposes only and is not medical advice, diagnosis, treatment or a recommendation to use BPC-157, TB-500 or any peptide. Neither BPC-157 nor TB-500 is FDA approved for treating musculoskeletal injuries, pain or routine recovery, and the BPC-157/TB-500 combination has not been established as safe or effective in controlled human clinical trials. Research-compound dosing and reconstitution information discussed later is provided to explain the Cellugenix research reference I use and should not be interpreted as a personal dosing protocol. Always discuss injuries, medications, peptides and treatment decisions with an appropriately licensed healthcare professional.

What Is the Wolverine Stack?

If you’ve been following Peptide Class, you know I’m especially interested in peptides that may have relevance for men over 40, 50 and 60.

And when we get into the category I call Healing, Regeneration & Recovery Peptides, two names come up again and again:

BPC-157 and TB-500.

Put them together and the combination has become known throughout the peptide community as the Wolverine Stack—a nickname inspired by the Marvel character famous for his extraordinary ability to heal.

Let’s get something straight immediately, though.

You aren’t going to suddenly heal like Wolverine.

 

And “Wolverine Stack” isn’t a recognized medical term. It’s a nickname used by peptide clinics, researchers, vendors and online peptide communities for combining BPC-157 with TB-500.

The reason I’m fascinated by this combination isn’t the name.

It’s the idea behind combining two different repair mechanisms.

Instead of thinking:

BPC-157 + TB-500 = twice as much healing

think:

BPC-157 may influence one group of repair processes while TB-500-related biology may influence another.

That’s the proposed rationale for putting them together.

And this distinction is important because no controlled human study has demonstrated that BPC-157 and TB-500 work better together than either compound alone.

That doesn’t make the concept uninteresting.

It means we need to separate biological rationale from proven clinical benefit.

That’s exactly what we’re going to do.

First: What Is BPC-157?

BPC-157 stands for Body Protection Compound 157.

It is a synthetic 15-amino-acid peptide derived from a sequence associated with a protective protein found in gastric juice.

That’s the complicated explanation.

Here’s the eighth-grade version:

Think of BPC-157 as the “repair environment” side of the Wolverine Stack.

When tissue becomes injured, repairing it requires much more than simply making new cells.

The damaged area needs adequate circulation. Cells need to migrate. Fibroblasts and other repair cells need to function. Collagen and connective tissue need to remodel.

Preclinical BPC-157 research has reported effects involving angiogenesis, nitric-oxide signaling, cell migration, tendon fibroblasts and tissue repair. For example, laboratory research found BPC-157 promoted tendon fibroblast outgrowth, survival and migration through FAK-paxillin signaling.

Angiogenesis simply means:

Creating new blood vessels.

And why might that matter?

Because blood vessels are essentially your body’s delivery roads.

They carry oxygen, nutrients and other substances necessary for repairing damaged tissue.

You can have a construction crew ready to rebuild a house, but if the roads are closed and the building materials can’t reach them, you’re going to have a problem.

That’s a simple way to think about one proposed aspect of BPC-157 biology.

But there’s a HUGE caveat.

Most of the impressive BPC-157 injury-healing evidence comes from animal and laboratory research, not large randomized human clinical trials. A 2025 systematic review examining BPC-157 for orthopaedic sports medicine found 36 included studies but only one clinical musculoskeletal study, with the remainder preclinical.

So when somebody tells you:

“BPC-157 heals tendons.”

My response is:

The preclinical research is interesting. Human evidence remains very limited.

That’s a much more accurate statement.

Small labels could identify Blood Vessel Signaling • Cell Migration • Tendon Research • Tissue Protection.

What Is TB-500?

Now let’s look at the other half.

TB-500 is related to thymosin beta-4 biology.

Thymosin beta-4 is a naturally occurring 43-amino-acid peptide found throughout the body and involved in processes including actin regulation, cell migration and tissue repair. TB-500 is a synthetic fragment associated with the actin-binding region of thymosin beta-4.

This distinction matters.

You’ll frequently hear someone say:

“Human research proves TB-500 does X.”

Then you look at the paper…

And the researchers actually studied full-length thymosin beta-4, not necessarily the commercial TB-500 fragment being sold by research-peptide companies.

Those aren’t automatically interchangeable.

Now here’s the simple explanation of why the biology is interesting.

Think of TB-500 as helping study the “repair crew movement” side of healing.

Your cells contain a protein called actin.

Actin helps cells maintain their structure and—importantly—move.

When you’re repairing damaged tissue, repair cells have to physically get where they’re needed.

Thymosin beta-4 interacts with actin and has been investigated for effects involving cell migration, wound repair, angiogenesis and tissue remodeling.

Think about our construction-site analogy again.

BPC-157 research raises questions about improving the roads and environment around the construction site.

TB-500/thymosin-beta-4 biology raises questions about helping the workers move to where they’re needed.

That’s an oversimplification.

But it’s an incredibly easy way to understand why people became interested in combining these two compounds.

 

BPC-157 vs TB-500: What’s the Difference?

This is one of the most important questions for AEO because people constantly confuse these two peptides.

They’re not the same peptide.

BPC-157 is commonly investigated around angiogenic signaling, nitric oxide pathways, gastrointestinal protection and musculoskeletal tissue-repair models.

TB-500 is associated with the actin-binding region of thymosin beta-4 and is discussed primarily around cell migration, cytoskeletal activity and tissue repair.

The easiest way I can explain the difference is:

BPC-157 = help create a better repair environment.

TB-500 = help mobilize the repair process.

Again, that’s a teaching analogy—not proof of a clinical effect.

And now you can probably see where the Wolverine idea came from.

Why Combine BPC-157 and TB-500?

This is where things get REALLY interesting.

Imagine you’re rebuilding a damaged house.

• You need roads to bring supplies to the property.
• You need workers to reach the property.
• You need building materials.
• You need communication between everyone involved.

And then you need the actual rebuilding process.

Healing inside your body is obviously infinitely more complicated, but the analogy works.

BPC-157 and TB-500 are combined because they are hypothesized to influence different pieces of the repair process.

BPC-157 research has investigated pathways associated with blood-vessel formation, nitric oxide signaling and connective-tissue repair.

TB-500-related thymosin-beta-4 biology involves actin and cellular migration.

So the theoretical Wolverine Stack looks something like:

BPC-157 → repair environment + vascular signaling

PLUS

TB-500 → cell migration + cytoskeletal signaling

EQUALS

a potentially broader tissue-repair signal.

Durham Peptides describes essentially this rationale: BPC-157 as the angiogenic side and TB-500 as the cell-migration side.

But here’s where I’m going to disagree with some peptide marketing.

We cannot currently say science has proven they “work better together.”

No controlled human clinical trial has established synergy between BPC-157 and TB-500, and no peer-reviewed study has established an optimal combination ratio, clinical dose or injury-recovery outcome for the blend.

That’s a critical distinction.

Complementary mechanisms = plausible hypothesis.

Proven synergy = not established.

That’s how I want us talking about peptides in Peptide Class.

Why I’m Interested in the Wolverine Stack After 40

Here’s where this becomes personal for me.

At 57, I don’t train the way I did when I was 27.

Not because I don’t train hard.

I absolutely do.

But recovery matters more now.

Years of volleyball, Muay Thai, kettlebells, metabolic training and simply living an athletic life add up.

Right now I’m particularly interested in recovery involving my shoulder, knee and back, which is one reason the BPC-157/TB-500 combination caught my attention.

I’m using the Wolverine combination as part of my own peptide research.

That does NOT mean:

“Funk uses it, therefore you should.”

My experience is an N=1 experiment.

It isn’t clinical evidence.

I’m going to track what happens, how I feel, what changes and whether I notice meaningful improvements while continuing to do the things we already KNOW matter:

• Resistance training.
• Physio and rehab.
• Mobility.
• Sleep.
• Protein.
• Nutrition.
• Stress management.
• Appropriate load management.
• And recovery.

That’s important because peptides should never become an excuse to ignore the actual cause of an injury.

Why Recovery Becomes More Important for Men Over 40

One reason I’m putting Wolverine into Peptide Class isn’t simply because it’s popular.

It’s because recovery becomes increasingly important as you age.

After 40, maintaining muscle and strength becomes one of your biggest weapons for healthy aging.

But you can’t train consistently if you’re constantly sidelined by a pissed-off shoulder, knee, hip, tendon or lower back.

And that’s why the recovery conversation matters.

However, peptides shouldn’t replace diagnosis.

If your shoulder hurts because you have a significant rotator-cuff tear, injecting an experimental peptide doesn’t magically correct the mechanical problem.

If your back pain comes from nerve compression, stenosis, disc pathology or another structural issue, you still need to understand what’s happening.

Recovery tools should complement intelligent treatment—not replace it.

What Does the Research Say About BPC-157?

BPC-157 has accumulated an interesting body of preclinical research involving tendons, ligaments, muscles, gastrointestinal tissue and vascular signaling.

For example, a tendon-healing experiment found BPC-157 promoted tendon fibroblast outgrowth and migration.

But when you zoom out, the evidence hierarchy matters.

Most published BPC-157 research remains animal or laboratory research.

Human evidence is sparse.

That means statements such as:

“BPC-157 heals torn tendons.”

“BPC-157 fixes your rotator cuff.”

or

“BPC-157 repairs your gut.”

go beyond what controlled human evidence currently establishes.

I find BPC-157 scientifically interesting.

I personally research it.

But those two facts don’t turn animal research into human proof.

What Does the Research Say About TB-500?

This one requires even more careful wording.

There is meaningful research on thymosin beta-4, including human wound-healing research. Thymosin beta-4 has been investigated in areas such as dermal and corneal wound healing.

But remember what I explained earlier:

TB-500 and full-length thymosin beta-4 aren’t automatically the same thing.

TB-500 is a synthetic fragment associated with thymosin beta-4’s actin-binding region. A significant amount of evidence people cite when discussing TB-500 actually comes from studies involving full-length thymosin beta-4.

So if someone says:

“TB-500 has tons of human clinical trials.”

Look at what compound was actually studied.

That detail matters.

What Does the Research Say About the Wolverine Stack Itself?

This may be the most important paragraph in this entire article.

There are currently no controlled human clinical trials proving that the BPC-157 + TB-500 Wolverine Stack improves injury healing or recovery.

There is also no controlled evidence establishing that the combination works better than BPC-157 alone, TB-500 alone, rehabilitation alone or placebo.

Interestingly, one of the sources you sent me claims that the 1:1 ratio reflects how these compounds have appeared together in published research. However, broader evidence reviews I checked found no published controlled combination trial at all, so I would not repeat the claim that a 1:1 ratio is scientifically established.

That’s exactly why we research these claims rather than copying them.

The proposed mechanisms are interesting.

The individual preclinical data are interesting.

The anecdotal experiences are interesting.

But:

Interesting ≠ proven.

What Are the Potential Benefits Researchers Are Interested In?

When people investigate BPC-157 and TB-500, they’re generally interested in tissue repair, tendon and ligament recovery, muscle recovery, wound healing, cellular migration, angiogenesis and inflammation-related repair processes.

For men over 40, that creates obvious interest around stubborn training injuries and the ability to continue exercising consistently.

But I want to deliberately use the phrase “potential benefits researchers are interested in” rather than “what Wolverine will do for you.”

We don’t have sufficient human evidence to make that second statement responsibly.

Who Might Be Interested in Researching the Wolverine Stack?

From an educational standpoint, Wolverine tends to attract athletes and active adults interested in musculoskeletal recovery, particularly people dealing with stubborn tendon, ligament, muscle or joint problems.

But that doesn’t establish who is medically an appropriate candidate.

Neither compound currently has an FDA-approved indication for those purposes.

For someone dealing with an injury, the first step should still be:

Figure out what’s actually injured.

That’s particularly important after 40, when something you’ve been calling “tightness” for six months could actually be a tendon injury, arthritis, nerve issue or structural problem requiring a different approach.

Potential Side Effects and Risks

This is where the lack of human research becomes important.

When a peptide hasn’t gone through the normal pharmaceutical approval process, we don’t have the same level of information about long-term adverse effects, drug interactions, contraindications, optimal dosing or population-specific risks that we’d expect from an approved medication.

There are also product-quality considerations with research compounds, including identity, concentration, purity, sterility and storage.

Another concern comes from mechanism.

Because angiogenesis involves creating blood vessels, you’ll sometimes hear concerns about whether pro-angiogenic signaling could theoretically be problematic in someone with an active malignancy. That isn’t proof that BPC-157 causes cancer, and we shouldn’t make that leap. But it illustrates why “it helps healing” isn’t enough information to declare an experimental compound universally safe.

Who Should Avoid the Wolverine Stack?

Because neither BPC-157 nor TB-500 has an approved therapeutic label for musculoskeletal recovery, there isn’t a validated prescribing document telling us precisely who can safely use the combination.

That’s exactly why medical screening matters.

Anyone with active or previous cancer, significant cardiovascular disease, serious chronic disease, pregnancy, use of medications affecting clotting or wound healing, or an undiagnosed injury should be especially cautious about experimenting with unapproved compounds and should discuss the issue with an appropriately qualified clinician.

And if you’re a competitive athlete, there’s another major issue:

BPC-157 is prohibited by WADA.

Competitive athletes should check current anti-doping rules before using any peptide or research compound.

Cellugenix Wolverine Blend: Educational Research Reference

Now let’s separate clinical evidence from research-vendor information.

The Cellugenix reference material we’ve been using lists a Wolverine-style BPC-157/TB-500 blend containing 5 mg BPC-157 + 5 mg TB-500. The sheet’s research example reconstitutes the vial with 2 mL bacteriostatic water.

At that concentration, each milliliter contains:

2.5 mg BPC-157 + 2.5 mg TB-500.

Because a U100 insulin syringe contains 100 units per milliliter, 10 units contains 250 mcg BPC-157 + 250 mcg TB-500.

That’s concentration arithmetic—not evidence that this is the medically appropriate human dose.

The reference sheet lists 250 mcg + 250 mcg, 10 units, AM or PM, every day, for an eight-week research period followed by eight weeks off.

Again:

That’s the Cellugenix/reference research protocol we’re documenting. It is NOT an FDA-approved dosing protocol and has not been validated by a Wolverine Stack clinical trial.

I want that distinction crystal clear in every Peptide Class article.

Can You Buy BPC-157 and TB-500 Separately?

Yes.

This is another useful thing to understand.

The Wolverine Stack isn’t some newly invented third peptide.

It’s simply two separate peptides being combined.

You can research:

BPC-157 independently.

TB-500 independently.

Or a premixed/co-lyophilized BPC-157 + TB-500 blend.

A combined vial simplifies concentration calculations and keeps the ratio fixed.

Separate vials provide more flexibility because researchers can study each compound independently or change the relative amounts.

But convenience shouldn’t be confused with evidence that one formulation works better.

Is the 1:1 Wolverine Ratio Better?

We don’t currently know.

A 5 mg BPC-157 + 5 mg TB-500 vial creates a convenient 1:1 ratio. Durham Peptides argues that equal proportions make sense because the two proposed repair mechanisms receive equal emphasis and the math is easy.

That’s a reasonable formulation rationale.

But there is currently no controlled human trial demonstrating that 1:1 is the optimal biological ratio.

So I’d describe 1:1 as a common research formulation, not “the scientifically proven Wolverine ratio.”

That’s a small wording change with a HUGE difference in scientific credibility.

Can You Inject Wolverine Near the Injury?

This is another question I know we’re going to get.

You’ll frequently hear peptide users claim BPC-157 should be injected close to the injured tendon, joint or muscle.

The problem is that we don’t have good controlled human evidence demonstrating that localized subcutaneous injection produces superior injury healing compared with systemic administration.

So I would not present site injection as an established advantage.

And injecting into or around an injured joint, tendon or other structure is absolutely not something I’d recommend people improvise themselves.

Frequently Asked Questions About the Wolverine Stack

What is the Wolverine Stack?

The Wolverine Stack is the popular peptide-community name for combining BPC-157 and TB-500 for research related to tissue repair and recovery. It is not a recognized FDA-approved treatment.

Why is it called Wolverine?

The nickname comes from the Marvel character Wolverine, who is famous for rapid healing. The name is marketing/community shorthand, not a scientific term.

What does BPC-157 do?

Preclinical research has investigated BPC-157 for effects involving angiogenesis, nitric-oxide signaling, cell migration, tendon fibroblasts and tissue repair. Human clinical evidence remains limited.

What does TB-500 do?

TB-500 is associated with thymosin-beta-4 biology and actin regulation, which is involved in cell movement and tissue repair. Much of the stronger research frequently attributed to TB-500 actually involves full-length thymosin beta-4 rather than the TB-500 fragment.

Why combine BPC-157 and TB-500?

The theory is that their mechanisms may complement each other: BPC-157 research involves vascular and connective-tissue signaling while thymosin-beta-4/TB-500 biology involves cytoskeletal regulation and cell migration. The proposed synergy has not been proven in controlled human trials.

Is Wolverine good for shoulder injuries?

There isn’t adequate controlled human evidence demonstrating that the BPC-157/TB-500 combination heals shoulder injuries.

What about knee injuries?

The same answer applies. The biological rationale is interesting, but we don’t currently have controlled clinical evidence establishing Wolverine as a treatment for knee injuries.

What about back pain?

Back pain can come from muscles, discs, facet joints, SI joints, nerves and many other structures. Wolverine should not be presented as a general treatment for back pain, and identifying the actual source of pain is important.

How long does Wolverine take to work?

There is no scientifically established human timeline for the combination. Claims that everyone should notice healing within a specific number of days aren’t supported by controlled human evidence.

Is the Wolverine Stack FDA approved?

No.

Is the Wolverine Stack safe?

We don’t have sufficient controlled human research on the combination to establish its long-term safety profile.

Is BPC-157 better than TB-500?

We don’t know. They aren’t interchangeable compounds, and there isn’t adequate comparative human research demonstrating that one is universally superior.

Can BPC-157 and TB-500 be purchased separately?

Yes. They are separate compounds. “Wolverine” simply refers to combining them.

Is a 1:1 ratio scientifically proven to be best?

No. A 1:1 formulation is convenient and commonly discussed, but no controlled human study has established it as the optimal ratio.

My Bottom Line on the Wolverine Stack for Men Over 40

This is why I’m excited about doing BPC-157 + TB-500 as this week’s Peptide of the Week.

From a biological standpoint, I think Wolverine is one of the most interesting experimental recovery and tissue-repair combinations for men over 40.

BPC-157 brings an intriguing body of preclinical research around vascular signaling, tendon cells and tissue repair.

Thymosin-beta-4/TB-500 biology brings another fascinating piece involving actin, cellular movement and repair.

Put them together and there is a logical hypothesis for why the combination might be useful.

But I’m not going to tell you:

“Science proves Wolverine heals injuries.”

It doesn’t.

Not yet.

There is no controlled human Wolverine trial establishing that.

And this is where I want Peptide Class to be different.

• I’m going to research these peptides.
• I’m going to follow emerging human studies.
• I’m going to look at protocols being used in the peptide world.

And when I’m personally experimenting with something, I’ll tell you about my experience—including my current interest in using this combination alongside my broader approach to my shoulder, knee and back.

But I’ll never pretend my experience equals clinical proof.

Peptides aren’t magic.

If you’re 47, 57 or 67, the foundation of recovery still includes intelligent strength training, rehabilitation when necessary, adequate protein and nutrition, mobility, sleep, stress management and managing your training load.

The Wolverine Stack is an experimental tool being explored on top of that foundation—not a replacement for it.

And that’s exactly why I think it deserves its own Peptide Class.

Scientific References

A useful starting point for BPC-157 is Chang and colleagues’ research on tendon fibroblast outgrowth, survival and migration, published in the Journal of Applied Physiology.

For thymosin beta-4, Goldstein, Hannappel and Kleinman’s review explains its actin-sequestering activity and proposed role in tissue repair, while Malinda and colleagues investigated thymosin beta-4 in wound healing.

The more recent BPC-157 evidence reviews are particularly important because they highlight the central limitation of this field: the enormous gap between the amount of preclinical enthusiasm and the amount of controlled human evidence.

And for the Wolverine combination itself, current evidence reviews find no controlled clinical trial demonstrating efficacy or synergy for BPC-157 + TB-500 together.

 

Affiliate Disclosure

I am an affiliate partner with Cellugenix Peptides. I research peptide companies, products and available testing information as part of my Peptide Class work, and Cellugenix is one of the companies I currently work with. If you purchase through my affiliate link or use my discount code FUNK15, you may receive a discount and I may earn a commission.

That relationship does not change how I discuss the science.

Cellugenix products are sold as research compounds, and they should not be confused with FDA-approved medications or compounds proven effective through controlled clinical trials. My goal with Peptide Class is to do the research, separate promising biology from established human evidence, share my own experiences transparently, and help you better understand what we know—and what we still don’t know.